Cancer 0 comments on Cancer Registrars Combat Cancer

Cancer Registrars Combat Cancer

The American Cancer Society reports that in 2010 more than 1,500 people each day will die of cancer. It is the second most common cause of death and accounts for nearly 1 of every 4 deaths in the United States. Cancer Registrars are the cancer data management experts that review the medical records and code, classify and enter disease related data into highly specialized databases used to study cancer treatment methods, outcomes and survival.

Healthcare is rapidly evolving to take advantage of scientific and clinical breakthroughs that enable physicians to diagnose and treat cancer patients using the latest technology to deliver the best quality of life or achieve the best possible outcomes. Cancer Registrars collaborate with the healthcare team to make this possible. While cancer registrars are familiar with changes in reporting standards and guidelines, in the year 2010 they experienced an unprecedented degree of change necessary to keep pace with targeted therapies, personalized and evidence-based medicine.

After review of the Obama-Biden Plan to Combat Cancer it is evident that the cancer registrar will experience even more radical change in how they perform their data collection and analysis duties to meet these national healthcare goals. By looking at outcome measures linked to monetary rewards, physicians and healthcare organizations will need to rely on the cancer registrar, more than ever, to provide data to support compliance with best practice standards.

Cancer Registrars are positioned in the allied health field to provide the expertise, skill and clinical knowledge to perform data analysis and outcomes studies. As physicians, cancer program directors and hospital administrators become more comfortable with the cancer registry and the value they contribute to the bottom line, the cancer registry profession will grow and be recognized as a vital component to cancer healthcare and as the cancer data management experts they have become.

Careers in cancer registry, as part of the Health Information Technology industry, are already increasing in response to the demand for outcomes related data. Individuals interested in this profession should immediately seek the services of a cancer registry coach and mentor to help them discover the lifelong opportunities for employment in this promising allied health profession.

You have permission to repost this article as long as you do not alter it in any way, give credit to the author and link back to her website.

Cancer 0 comments on How Is Prostate Cancer Treated

How Is Prostate Cancer Treated

Doctors and scientists have always tried to discover as many treatments for prostate cancer. There are a lot of ways in which prostate cancer can be treated and more are found each day.

First of all people must know that treatments for prostate cancer are depending on several factors. Age, the extent of the cancer or the medical condition in which the patient is are one of many. Furthermore every person should be discuss with his doctor the kind of treatment he may be given and choose from several depending on the side-effects.

When one has: a problem in emptying his bladder, bladder stones, an enlarged prostate, slow urination or a first or second stage cancer, he must immediately start treatment. There are also cases when one must only wait and monitor his prostate cancer, for not all tumors are fast growing and people can do very well without treatment.
This may be the case especially in older men with medical problems. Monitoring the cancer involves regular visits to the doctor. They make tests, rectal examinations and even x-rays to follow the growing of the tumor and determine if treatment is necessary. This waiting can be very useful because the patient will not suffer from any side effect.

If the doctor has monitored your situation and has concluded that treatment is necessary, you may be faced to one of this treatments:

An operation to remove the prostate gland, called radical prostectomy.

Radiation treatment, which can be of two types: external beam or implant of radiation.

Therapy by radiation, but when the prostate cancer has spread.
Therapy through an external beam , which is pointed directly at the cancer.
An implant of a radioactive pallet, of small caliber, inserted into the prostate. It can generate radioactivity from a few weeks to months and doesnt have to be removed after.

These treatments can cause several side effects of significant importance. When using the external beam irritation, skin burn or even loosing hair is most likely. These effects may also be permanent. There is also the case of becoming impotent or the inability to keep urine, side effects found in using both of the radiation treatments.

Treatment by using hormones is another method, but not likely to be given in cases where the prostate cancer has spread. Their purpose is to reduce the level of testosterone or even stop it from working. At first this tretment may work, but in time the cancer may progress. Here are some ways for the hormonal treatment:
-Removing by surgery the testicles.
-Using drugs or agents such as flutamide or bicalutamide.
-Using estrogen(it has strong side effects).

Like any other cancer treatment this two has side effects such as vomiting, impotence, nausea or the enlargement of the breasts.

Finally there is chemotherapy. This treatment is not very used cause it is very toxic and has many side effects.

Cancer 0 comments on Screening Tests Disclose Possibility Of Prostate Cancer But Physician Does Not Notify Patient

Screening Tests Disclose Possibility Of Prostate Cancer But Physician Does Not Notify Patient

Men frequently possess a poor comprehension of prostate cancer, their own risk for the cancer, and the methods available for detecting whether they have prostate cancer. Many men have little, if any, understanding of the value of screening for prostate cancer or of the guidelines for when they should commence testing, how frequently to screen, and the meaning of screening test results. Regrettably doctors sometimes fail to screen male patients or wait too long prior to ordering diagnostic testing subsequent to an abnormal result from a screening test.

There are several various factors that can result in a delayed diagnosis. One common type of medical error that forms the basis for these cases comes about when the male patients primary care physician (1) orders a PSA blood test, (2) notices abnormally high levels of PSA and but (3) neither tells the patient about the abnormal results (and what they indicate) nor orders diagnostic tests, such as a biopsy, to rule out prostate cancer. The case below is an example of this problem.

A doctor, an internist, discovered that his male patient had a PSA of 8. (a level above a 4.0 is generally thought to be high). The doctor did not tell the patient. The physician failed to refer the patient to a urologist. The doctor failed to order a biopsy. Two years later the doctor repeated the PSA test. This time the PSA level had risen to 13.6. Once again, the doctor did not inform the patient. Again, the doctor did not refer the patient to a urologist. And again, the doctor did not order a biopsy. Two years later the physician repeated the PSA test. It was not until three years after first knowing about the patients raised PSA level that the doctor finally told him that he most likely had cancer. More testing showed that at this point he had advanced prostate cancer. A prostatectomy was no longer an option. Rather the patient underwent radiation therapy and hormone therapy in an effort to impede the further progression of the cancer. The law firm handling this matter announced that the case went to mediation and settled in the amount of $600,000.

But doing nothing after observing abnormal test results results in a situation in which those patients who do actually have prostate cancer might not find out they have it until it has spread outside the prostate, decreasing the patients choices for treatment, and substantially lessening the chances that the patient will be able to survive the cancer.

This lawsuit illustrates a sort of mistake that can result in the delayed diagnosis of a patients prostate cancer. It occurs when the physician actually follows the guidelines and screens male patients for prostate cancer yet does not follow through when the test results are abnormal.

Cancer 0 comments on Esophageal Cancer Therapeutics Pipeline Assessment And Market Forecast To 2017

Esophageal Cancer Therapeutics Pipeline Assessment And Market Forecast To 2017

Esophageal Cancer Therapeutics Market is forecast to Show High Growth Until 2017, The report identifies the key trends shaping and driving the global Esophageal Cancer Therapeutics market.

GlobalData estimates that the global esophageal cancer therapeutics market was valued at $243.8m in
2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 14% over the next seven
years, to reach $594.7m by 2017. This fast growth is primarily attributed to the strong pipeline and onset of four promising molecules from 2014 onwards. The HER-2 expressing patients have access to
Herceptin (transtuzumab) which is approved for HER2-overexpressing metastatic gastroesophageal (GE)
junction adenocarcinoma along with some widely used off-label drugs such as cisplatin and capecitabine
and ECF (epirubicin,cisplatin and 5-FU) which have gone off-patent.

GlobalData analysis shows that the esophageal cancer therapeutics pipeline is strong, with 35 molecules
in various phases of clinical development, including 31 first-in-class molecules. The four promising first-inclass products such as Avastin (bevacizumab), Erbitux (cetuximab), ramucirumab and Tykerb (lapitinib) in late stage pipeline are expected to hit the market around 2014. These products possess mechanisms of action different from currently used drugs. Thus the pipeline for the esophageal cancer therapeutics
market is strong.

For Sample Pages, please click or add the below link to your browser:

The esophageal cancer therapeutics market is represented by Herceptin and some off-label drugs.
Cisplatin, Xeloda (capecitabine) and ECF are mainly used drugs for treating esophageal cancer.
Paclitaxel and carboplatin, 5-FU and leucovorin are also used but they have low response rates.
Herceptin from Genetech/Roche is prescribed as the first line and second line form of drug therapy for the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma patients. There are no other drugs which have been approved for non HER-2 overexpressing patients of esophageal cancer. Any drug that could successfully cater to this untreated patient segment is expected to reap revenues from the esophageal cancer therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, Esophageal Cancer Therapeutics Pipeline Assessment and Market Forecasts to 2017. The report is an essential source
of information and analysis on the global Esophageal Cancer Therapeutics market. The report identifies
the key trends shaping and driving the global Esophageal Cancer Therapeutics market. The report also
provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global Esophageal Cancer Therapeutics
sector. This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalDatas team of industry experts.

For further details, please click or add the below link to your browser:

Visit our report store:

For more details contact:

North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

Cancer 0 comments on Esophageal Cancer Therapeutics – Pipeline Assessment And Market Forecast To 2017

Esophageal Cancer Therapeutics – Pipeline Assessment And Market Forecast To 2017

Esophageal Cancer Therapeutics Market is forecast to Show High Growth Until 2017, The report identifies the key trends shaping and driving the global Esophageal Cancer Therapeutics market.

GlobalData estimates that the global esophageal cancer therapeutics market was valued at $243.8m in
2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 14% over the next seven
years, to reach $594.7m by 2017. This fast growth is primarily attributed to the strong pipeline and onset of four promising molecules from 2014 onwards. The HER-2 expressing patients have access to
Herceptin (transtuzumab) which is approved for HER2-overexpressing metastatic gastroesophageal (GE)
junction adenocarcinoma along with some widely used off-label drugs such as cisplatin and capecitabine
and ECF (epirubicin,cisplatin and 5-FU) which have gone off-patent.

GlobalData analysis shows that the esophageal cancer therapeutics pipeline is strong, with 35 molecules
in various phases of clinical development, including 31 first-in-class molecules. The four promising first-inclass products such as Avastin (bevacizumab), Erbitux (cetuximab), ramucirumab and Tykerb (lapitinib) in late stage pipeline are expected to hit the market around 2014. These products possess mechanisms of action different from currently used drugs. Thus the pipeline for the esophageal cancer therapeutics
market is strong.

For Sample Pages, please click or add the below link to your browser:

The esophageal cancer therapeutics market is represented by Herceptin and some off-label drugs.
Cisplatin, Xeloda (capecitabine) and ECF are mainly used drugs for treating esophageal cancer.
Paclitaxel and carboplatin, 5-FU and leucovorin are also used but they have low response rates.
Herceptin from Genetech/Roche is prescribed as the first line and second line form of drug therapy for the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma patients. There are no other drugs which have been approved for non HER-2 overexpressing patients of esophageal cancer. Any drug that could successfully cater to this untreated patient segment is expected to reap revenues from the esophageal cancer therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, Esophageal Cancer Therapeutics – Pipeline Assessment and Market Forecasts to 2017. The report is an essential source
of information and analysis on the global Esophageal Cancer Therapeutics market. The report identifies
the key trends shaping and driving the global Esophageal Cancer Therapeutics market. The report also
provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global Esophageal Cancer Therapeutics
sector. This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalDatas team of industry experts.

For further details, please click or add the below link to your browser:

Visit our report store:

For more details contact:

North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

Cancer 0 comments on Ovarian Cancer Treatment And Surgery In India Is It A Need

Ovarian Cancer Treatment And Surgery In India Is It A Need

Any cancerous growth arising from the ovary is termed as Ovarian Cancer. Most of the ovarian cancers are surface level of the ovary, rising from the skin. Another source is the fallopian tube, which since it is connected to the ovary has similar effects as ovarian cancer. Egg cells and supporting cells also cause gynaecological cancer. The symptoms of ovarian cancer are bloating, pelvic pain, frequent urination, etc. In India, during 2001-06, incidence rates for ovarian cancer varied from 0.9 to 8.4 per 100,000 person years. The highest incidence was noted in Pune and Delhi areas. With such increasing rates, Medical Tourism India is trying to go to all means to come up with easier, safer and most economical methods of treatments for ovarian cancer.
The exact cause of ovarian cancer is still unknown. There can be hereditary causes as well as physiological and biological causes. Women with endometriosis and post menopausal estrogen replacement therapy are at a higher risk than others. The more number of times a woman gives birth, the lesser is the risk for ovarian cancer. Another study shows that the women who use more of oral contraceptives have lesser risk of developing ovarian cancer. The most obvious way of preventing ovarian cancer is the removal of the ovaries via surgery. Ovarian Cancer Treatment and Surgery in India has been improving throughout the years and has reached a remarkable stage where India is looked upon as the first choice for medical treatment by foreign nationals. India provides high quality medical treatments at economical rates and this attracts many countries. Millions of people come buzzing to India to avail the low cost and high quality services. The rising hospitals and the multi-faceted doctors are the reason all this has been possible.
It is very easy to detect ovarian cancer. A physical examination and a blood test is enough to diagnose it. An inspection of the abdominal cavity along with biopsies can confirm the diagnosis. Ovarian cancer is a little hard to diagnose at the earlier stages. Ovarian Cancer Treatment and Surgery in India has advanced to such a level that it has been classified into many categories according to the tumours associated. Ovarian epithelial carcinoma is the most common type and is a surface tumour. Germ cell tumours are generally benign and tend to occur in young women and girls. Sex cord-stromal tumours are generally malignant and occur mostly in post menopausal women.
Forerunners HealthCare provides all health solutions to any patient that comes to India for medical treatments. Medical consultations, checkups, hospital bookings, doctors” appointments, travel options, accommodation, etc are all arranged by the company. The company being Medical Tourism India”s finest consultant helps in guiding the patient and the family through all the stages of the consultation. With all the world”s best facilities made available by the association with all the leading hospitals and the best doctors, your medical experience will be wonderful and relaxing.

Cancer 0 comments on A Guide To The Relation Between Asbestos Exposure And Mesothelioma Lung Cancer

A Guide To The Relation Between Asbestos Exposure And Mesothelioma Lung Cancer

An understanding of asbestos is necessary before we try to understand mesothelioma lung cancer. Asbestos, a natural fibrous mineral, used commonly in construction process and manufacturing industries is detrimental to human health. Continuous inhalation of its fibers enhances the susceptibility to respiratory disorders and can lead to many dangerous diseases. A leading example of such dangerous disease is Mesothelioma lung cancer. Actually, mesothelioma lung cancer is misnomer because mesothelioma cancers affect the lining of lungs (pleura) and abdomen and not the lungs. Since mesothelioma cancers mostly affect the lining of the lungs, it is generally called mesothelioma lung cancer. The workers who had worked in industries such as shipbuilding, asbestos mining, and asbestos production are vulnerable to mesothelioma cancers.

Mesothelioma and the Role of Carcinogens:

What is mesothelioma cancer and how does the lining of the lung become cancerous? Cancer is a tumor that is malignant in nature. Tumor is formed when there is abnormal cell division and cell multiplication in the cancerous cells. Exposure to carcinogens or cancer-causing material like cigarette smoke, asbestos and silica dust is instrumental in this abnormal cell division and formation of tumor.

Mesothelioma cancer is directly linked to asbestos exposure. However, those already exposed to asbestos have a greater chance of developing lung cancer if they are exposed to other carcinogens such as cigarette smoke. A study reports that the workers with a history of asbestos exposure and cigarette smoke are more prone to lung cancer than the non-smokers and those with no history of asbestos exposure.

Complications Associated with Mesothelioma Cancer:

Normally, the latency stage for asbestos-related diseases in general and mesothelioma cancers of the lining of lung in particular, 20-50 years, which makes detection of Mesothelioma a complicated issue. This situation is further aggravated particularly where the worker is also addicted to cigarette smoking. By the time, the disease shows its symptoms, a considerable exposure to additional carcinogens linked to cigarette smoking has already taken place. This makes a worker more vulnerable to lung cancer besides the vulnerability to mesothelioma cancers.

Mesothelioma Cancers and Legal Redress:

The Government is conscious of the ill effects of asbestos exposure and the seriousness of mesothelioma cancer. The employees working in factories with significant risk of asbestos exposure are eligible for Mesothelioma compensation, if the exposure is the cause of Mesothelioma. There has been a spate of lawsuits for seeking compensation for mesothelioma and lung cancers. In many cases, the courts have awarded heavy sums as compensation against the asbestos manufacturing companies.

Cancer 0 comments on Cancer Cell Powerpoint Template

Cancer Cell Powerpoint Template

To cure the most deadly disease of the world, chemotherapy is the most common method. The name of this deadly disease is cancer and it happens due to poisoning of cancer cells in a human body. It results in reduction of the healthy cells in bone marrow and affects gastrointestinal system. It also have devastating effects on several other organs of a human body which includes liver, kidneys, heart, lungs etc.

In the process of chemotherapy, the radiation that has the ability to kill cancer cells is involved. However, the repercussion of undergoing a chemotherapy includes burn, scars. It can also cause damage to healthy tissues and body organs.

There is also an effective way to fight cancer. This is to destroy the cancer cells by starving. In this way, the foods on which cancer cells depend could no longer reach them. This would prevent the cancer cells from getting a chance to get multiplied. The food due to which the cancer cells can bolster up are

*Sweets

*Milk

*Meat

*Distilled Water

*Caffeine

*High protein diet

Certain other things which are required to be considered are

*Avoid using plastic containers in the microwaves.

*Do not use plastic bottles in freezer.

*Try to avoid plastic wrap in microwave.

Also, in a human body, every single cancer cell gets registered an electrical charge across the membrane/s plasma. Cancer cells have also proved to contain low energy as well as a low level of cellular energy production. The transmembrane potential in these cells is at 15 millivolts which indicates the low level of energy.

The cancer cells which have low transmembrane potential at 15 millivolts divide themselves into two separate cells. The reason behind this is that the energy level drops into life-threatening levels. The existence of the cell is also threatened. The cell than begins to proliferate uncontrollably in an attempt to save itself and continue to grow. As the cell continues to rapidly proliferate amongst these cancerous cells, the amount of energy that is produced within the cells is even further diminished.

Many of the clinicians are, very often, required to make presentations regarding the diagnosis, assessment and treatment of this deadly disease. The Cancer Cell Powerpoint Template and cancer cell PPT slides help them to represent the status of the disease more accurately and efficiently. These blue prints enables a better understanding of the concepts to the viewers. It is due to the fact that these layouts are editable. Also, the users can add various types of graphics in order to make the presentations attractive and exclusive. These cancer cell PPT templates and cancer cell PPT slides also help the users to make their presentations more professional and catchy and help to make a mark in the minds of the viewers.

For more details you can visit

Cancer Cell Powerpoint Template

Cancer 0 comments on Reading this – information on vulvar cancer

Reading this – information on vulvar cancer

Recent studies have found that natural compounds of graviola, acetogenins have superb property to inhibit the enzyme processes that are specifically present in membrane of cancerous cells. Graviola cancer cure is still under investigation, but it is clearly inspiring that it is used world widely for its potential to cure serious ailments.

In this plant screening program, it is cancer cures illustrated that graviola stem and leaves demonstrated active toxic effects against cancer cells.In various vitro clinical trials, it has been studiedthat specific phytochemical acetogenins that are found in graviola herb, have been shown their selective toxic effects against various cancerous cells like lung carcinoma cell lines, prostate adenocarcinoma, breast tumor lines, liver cancer cell lines, pancreatic carcinoma cell lines, colon adenocarcinoma cell lines and multi-drug resistant breast adenocarcinoma. Along with the antitumourous effects of graviola, it is also discovered that the compound annonaceous acetogenins which are found in graviola herb, also exhibit antiparasitic, insecticidal, and antimicrobial activities. .

Anti-cancerous effects of graviola have been demonstrated in various vitro studies, and because of its traditional usage it is touted as cancer fighting herbal supplement. Graviola is an exciting cancer alternative remedy which medicinal properties have information on vulvar cancer been recognized for centuries by the native population of Amazon.

The graviola (Annona muricata) leaves possess antioxidant potential and play a role as an effective radical scavenger and augments its therapeutic effects. National Cancer Institute has been also explored the toxic effects of graviola against cancerous cells in its plant screening program in 1976.

Some researches have confirmed that annonaceous acetogenins has potent anti-tumor properties and exhibit selective toxic property against tumor cells. Graviola contains many active compounds and chemicals which have numerous healing properties; one of them is natural phytochemicals known as annonaceous acetogenins which is the main focus of researchers.

Graviola extracts, Graviola powder other and Graviola supplements are easily available to promote optimal health and can be taken as general health tonic. Other clinical findings conducted by scientists of Taiwan suggested that at very low dosages, annonaceous acetogenins of graviola exhibited highly toxic effects particularly to ovarian, breast, cervical, bladder and skin cancer cell lines.

reference: Reading this – information on vulvar cancer

Cancer 0 comments on Generic Drugs For Prostate Cancer To Escalate Market Growth

Generic Drugs For Prostate Cancer To Escalate Market Growth

According to a new report by RNCOS, Cancer Generics Market Analysis, the global cancer generics market has been advancing at a robust pace over the past few years. Patent expiries of blockbuster branded drugs support the growth of this market in a significant manner, thereby fetching billion of dollars. Moreover, the future holds enormous growth potential for the sector as there are many drugs under development stage. In such a scenario, the market for cancer generics is expected to grow at a healthy CAGR of around 26% during 2011-2015.

Our research report has found that prostate cancer is the second most regularly diagnosed cancer in men and the fifth most widespread cancer in general. Incidence rates for prostate cancer are on a rise. The future holds tremendous growth for prostate cancer generics as key drugs, such as Leuplin (Abbott) and Eligard (QLT Inc) are likely to loose their patent in a decade. This will generate a multi-billion dollar market for prostate cancer generics players.

The report, which is spread in over 70 pages, covers all the key aspects of the global cancer generics market taking into account all the factors that are responsible for the current and future growth. It investigates the current market drivers and trends that are likely to impact the future developments in the US NIPD sector. Further, it also evaluates the current status and future potential of generic drugs in most common cancers worldwide, such as lung cancer, breast cancer, colon cancer, stomach cancer, and prostate cancer.

The report is an outcome of an extensive research and in-depth analysis of the current status and expected position of the global cancer generics market. It illustrates the market drivers, key developments, and restraints that may impact the market in an effective manner. A brief description of active market players, such as Teva, Accord Healthcare, Mylan, and Sun Pharmaceuticals has also been provided. Overall, the report is an optimum source of knowledge and statistics for the clients interested to enter or expand in cancer generics market.

For FREE SAMPLE of this report visit:

Some of our Related Reports are:

– Japan Generics Market Analysis ()
– Generic Drug Market in Canada ()
– Booming Generics Drug Market in India ()
– UK Generics Market Analysis ()
– Booming US Generic Drug Market ()

Check Related REPORTS on:

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.